✦ LIBER ✦

Myc and Mammary Cancer: Myc is a Downstream Effector of the ErbB2 Receptor Tyrosine Kinase

✍ Scribed by Nancy E. Hynes; Heidi A. Lane

Book ID: 110274981
Publisher: Springer US
Year: 2001
Tongue: English
Weight: 662 KB
Volume: 6
Category: Article
ISSN: 1083-3021
DOI: 10.1023/a:1009528918064

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

EXPRESSION OF THE TYPE 1 TYROSINE KINASE

EXPRESSION OF THE TYPE 1 TYROSINE KINASE GROWTH FACTOR RECEPTORS EGF RECEPTOR, c-erbB2 AND c-erbB3 IN BLADDER CANCER

✍ RAJKUMAR, THANGARAJAN; STAMP, GORDON W. H.; PANDHA, HARDEV S.; WAXMAN, JONATHAN; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 704 KB

Expression of the c-erbB3 protein was determined in transitional cell carcinoma of the bladder by immunohistochemistry. Strong membrane staining was observed in 10 per cent of cases (7/70) and cytoplasmic and membrane overexpression in 20 per cent (14/70). Overexpression of the epidermal growth fact

The PEA3 Ets transcription factor is a d

The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase

✍ O'Hagan, Rónán C; Hassell, John A 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 358 KB

High cell kinetics is associated with am

High cell kinetics is associated with amplification of the int-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers

✍ Alma Contegiacomo; Claudia Pizzi; Laura De Marchis; Maurizio Alimandi; Paolo Del 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 773 KB

Cell kinetics, is a predictive parameter of breast-cancer aggressiveness, and mutations occurring in mammary tumorigenesis may favor iuncontrolled cell proliferation. In this study, cell kinetics, clinico-pathological characteristics and genetic alterations at the irrt-2, bcl-I, c-myc, c-erbB-2, and

ZD1839 (Iressa), a novel epidermal growt

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

✍ Neil G. Anderson; Tawhid Ahmad; Kai Chan; Richard Dobson; Nigel J. Bundred 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 192 KB 👁 1 views

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro